Dasatinib (BMS-354825), Inhibitor

Dasatinib (BMS-354825)

Cat. Num. AAA386202

• Purity: >98%
• Synonyms: Dasatinib (BMS-354825); Sprycel; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 20.49 mL (1 mg); 102.46 mL (5 mg); 204.92mL (10 mg); 0.5 mM: 4.1 mL (1 mg); 20.49 mL (5 mg); 40.98 mL (10 mg); 1 mM: 2.05 mL (1 mg); 10.25 mL (5 mg); 20.49 mL (10 mg); 5 mM: 0.41 mL (1 mg); 2.05 mL (5 mg); 4.1 mL (10 mg) (varies by lot)

• CAS Number: 302962-49-8
• Formula: C22H26ClN7O2S
• SMILES: CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C
• Actions: Inhibitor
• In Vivo Solvent: 1% DMSO/30% polyethylene glycol/1% Tween 80
• Solubility (DMSO): 98 mg/mL (200.81 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (in vivo): 30 mg/mL
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for Dasatinib (BMS-354825), inhibitor

Dasatinib (BMS-354825) is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor. The main targets of dasatinib, are BCR/ABL, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2.

References

Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
Sano T, .et al. Gliding Basal Cell Migration of the Urothelium during Wound Healing, Am J Pathol, 2018, Nov;188(11):2564-2573 PMID: 30121259
Ines Peschel, .et al. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia, Haematologica, 2017, Aug; 102(8): 1378-1389 PMID: 28522571
Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
John D. Leonard, .et al. Identification of natural regulatory T cell epitopes reveals convergence on a dominant autoantigen, Immunity, 2017, Jul 18; 47(1): 107-117.e8. PMID: 28709804
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358